名稱 | ADCC Bioassay Effector Cell V variant (High Affini |
型號(hào) | CBP74003 |
報(bào)價(jià) | |
特點(diǎn) | ADCC Bioassay Effector Cell V variant (High Affinity)-Fcγ-NFAT/Jurkat,母細(xì)胞:Jurkat |
產(chǎn)品搜索
相關(guān)文章
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株 > CBP74003ADCC Bioassay Effector Cell V variant (High Affini
- 詳細(xì)內(nèi)容
I. Background | |
抗體依賴的細(xì)胞介導(dǎo)的細(xì)胞毒性作用(ADCC,antibody-dependent cell-mediated cytotoxicity )是指抗體的 Fab 段結(jié)合病毒感染的細(xì)胞或腫瘤細(xì)胞的抗原表位,其 Fc 段與殺 傷細(xì)胞(NK 細(xì)胞、巨噬細(xì)胞等)表面的 FcR 結(jié)合,介導(dǎo)殺傷細(xì)胞直接殺傷靶細(xì)胞,它是 抗腫瘤的治療性抗體藥物發(fā)生作用的一種作用重要機(jī)制。 傳統(tǒng)用于測(cè)定 ADCC/ADCP 的方法主要依賴于相關(guān)原代免疫細(xì)胞的分離、體外分化, 進(jìn)而測(cè)量靶細(xì)胞的殺傷或吞噬效應(yīng)。這些方法高度依賴供體原代細(xì)胞,價(jià)格昂貴且費(fèi)時(shí)費(fèi) 力,對(duì)原代細(xì)胞的分離分化過程對(duì)實(shí)驗(yàn)操作的要求非常高,實(shí)驗(yàn)失敗風(fēng)險(xiǎn)較大,由于分離 分化細(xì)胞純度問題,還存在檢測(cè)信號(hào)低以及不穩(wěn)定均一的問題。另外,每次實(shí)驗(yàn)的細(xì)胞供體來源可能都不一致,實(shí)驗(yàn)結(jié)果可重復(fù)性較差,可能存在批次 差異。由于以上這些因素的影響,在需要高質(zhì)量控制的藥物開發(fā)過程中,很難建立穩(wěn)定可 靠的檢測(cè)方法。 | |
II. Description | |
ADCC Bioassay Effector Cell V variant (High Affinity)-Fcγ-NFAT Jurkat 報(bào)告基因藥靶模 型很好的模擬了體內(nèi) ADCC 的信號(hào)轉(zhuǎn)導(dǎo)過程,原理見下圖所示。
| |
III. Introduction | |
Host Cell: | Jurkat |
Expressed gene: | NFAT-Luc-CD16(V158) |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Synonym(s): | Antibody-dependent cell-mediated cytotoxicity |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | RPMI-1640+10%FBS+300μg/ml hygromycin+1μg/ml puromycin |
Mycoplasma Testing: | Negative |
Storage: | Immediately upon receipt, store in liquid nitrogen. |
Application(s): | Functional(Report Gene) Assay |
IV. Description of Host Cell Line | |
Organism: | Homo sapiens, human |
Tissue: | Peripheral blood |
Disease: | Acute T cell leukemia |
Morphology: | Lymphoblast |
Growth Properties: | Suspension |
Ⅴ. Representative Data |
Figure 2. Recombinant ADCC Bioassay Effector Cell V variant (High Affinity)-Fcγ-NFAT/Jurkat stably expressing CD16a(V158).
Figure 3. Dose response of CD20 Ab in ADCC Bioassay Effector Cell (High Affinity)-Fcγ-NFAT Jurkat cell(C36). Dose response of TNFα Abs in ADCC Bioassay Effector Cell V variant(High Affinity)-Fcγ-NFAT Jurkat cell(C36)with Membrane Anchored TNFα Cells(Suspended,C5).
Figure 4. Dose response of TNFα Abs in ADCC Bioassay Effector Cell V variant(High Affinity)-Fcγ-NFAT Jurkat cell(C36)with Membrane Anchored TNFα Cell (Adherent,C12).